Good MorningEquities began the week on stable footing despite the previous week's large decline and the upcoming FOMC announcement on Wednesday. The Fed is expected to raise interest rates by 75 basis points on Wednesday and provide an outlook for the future of Fed policy. It is largely believed the Fed will continue to raise rates into the beginning of 2023 but at a much slower pace than what it has set so far. The risk is that inflation data will continue to accelerate as it has and push the Fed into ramping its posture once again.
On the economic front, the NAHB home builders survey declined to a new low as demand and traffic dry up. The news is only the latest in a string of poor housing data that points to a major contraction in the industry and one that will have rippling effects throughout the economy. Also on tap this week is a read on building permits and housing starts as well as existing home sales and the Index of Leading Indicators. Featured: Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad) 
|
Technology | | Database and cloud solutions provider Oracle (NASDAQ: ORCL) stock got smoked on its fiscal Q1 2023 earnings report. Shares were holding up relatively well until the Company revealed the extent of damage from FX related headwinds. Up until 2022, FX headwinds didn’t really impact stocks too much... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Consumer Discretionary | |
Lucid is in a better financial position than most upstart EV players
The near-term headwinds should matter little in the long haul
Lucid noted that its liquidity position will keep it running well into 2023
Like most electric vehicle plays, Lucid Group, Inc. (NASDAQ: LCID) has had its shar... Read the Full Story |
|
Consumer Staples | |
Hormel Foods Corporation (NYSE: HRL) , of SPAM, Dinty Moore stews and other canned lunch meat fame, is a good-sized Dividend King titan. The proof: Its 56-year track record of dividend increases. Let's put Hormel Foods Corporation under the microscope and take a look at the pros and cons of invest... Read the Full Story |
|
From Our Partners | | Hedge funds are rotating out of AI hype and into the hardware layer powering it. New research identifies three profitable U.S. infrastructure companies leading this shift.
One just posted 76% year-over-year data-center growth. Another holds a $12 billion backlog from global hyperscalers. A third is generating 59%+ gross margins on next-gen chips. | | Access the full analysis, price setups, and catalysts now |
|
Consumer Discretionary | |
McDonald’s continues to be able to deliver growth
McDonald’s goes about its business ringing up sales to value-minded eaters
McDonald’s has a steady history of quarterly dividend distributions
Just like you know what you’re getting when you order the number 5 value m... Read the Full Story |
|
Industrials | |
FedEx (NYSE: FDX) fired a warning shot the market needs to pay attention to when it prereleasedQ3 earnings but there is more to the story than what the headlines are screaming. FedEx is predicting a global recession in 2023 but the 20% decline in share prices is already offering a buying opportuni... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
The market for Autozone (NYSE: AZO) stock pulled back from a fresh all-time high ahead of the FQ4 earnings release because there was cause for concern. Not only was the stock trading at an above-average P/E for the S&P 500 (NYSEARCA: SPY) and well above its peer Advance Auto Parts (NYSE: AAP) ... Read the Full Story |
|
Industrials | | The world’s largest freelance marketplace platform Upwork. Inc. (NASDAQ: UPWK) shares can’t seem to catch a break as they trade down (-52.6%) on the year. Despite strong industry tailwinds projecting nearly 500 million worldwide freelancers by 2030, the sentiment on the stock continues t... Read the Full Story |
|
Consumer Staples | | Grocery chain operator The Kroger Company (NYSE: KR) stock is trading up 4.5% in 2022 far outperforming tech stocks and the benchmark indices. The Company operates approximately 2,800 grocery store and pharmacies under two dozen banners in the 35 states and also sells fuel through over 1,600 centers... Read the Full Story |
|
Technology | | Riddle me this, how do you shock investors into a two-day selling frenzy vaporizing (-20%) off your share price and (-30%) off your market cap just after releasing great earnings? Answer, by announcing a cash and stock acquisition paying 50X sales ($20 billion) for a company with $400 million ARR in... Read the Full Story |
|
Markets | | The Inflation Reduction Act (IRA) was signed into law by President Joe Biden on August 16, 2022. The intent of which is to lower inflation by lowering the costs for health, raise funding for the IRS, and funding decarbonization efforts through energy and climate projects reducing carbon emissions by... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. | | View Today's Stock Pick |
|
